CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing ...

Read more about Future pandemics may be fought faster with mRNA and advanced vaccine platforms on Devdiscourse ...

Moderna (NASDAQ:MRNA) has cancelled plans to build a messenger RNA manufacturing plant in Japan, citing concerns over the current business environment, the Japanese business publication Nikkei Asia ...

Newly accredited GMP facility for commercial manufacturing of mRNA in anticipation of customer BLA submission. Kaneka Eurogentec, an FDA, EMA inspected CDMO focused on the production of injectable ...

Moderna (MRNA) announced on Wednesday that it has completed its domestic end-to-end mRNA manufacturing network with the onshoring of drug product manufacturing to its Moderna Technology Center in ...

New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled ...